Literature DB >> 25583720

In vitro antibiotic susceptibilities of Yersinia pestis determined by broth microdilution following CLSI methods.

Henry S Heine1, Jeremy Hershfield2, Charles Marchand2, Lynda Miller2, Stephanie Halasohoris2, Bret K Purcell2, Patricia L Worsham2.   

Abstract

In vitro susceptibilities to 45 antibiotics were determined for 30 genetically and geographically diverse strains of Yersinia pestis by the broth microdilution method at two temperatures, 28°C and 35°C, following Clinical and Laboratory Standards Institute (CLSI) methods. The Y. pestis strains demonstrated susceptibility to aminoglycosides, quinolones, tetracyclines, β-lactams, cephalosporins, and carbapenems. Only a 1-well shift was observed for the majority of antibiotics between the two temperatures. Establishing and comparing antibiotic susceptibilities of a diverse but specific set of Y. pestis strains by standardized methods and establishing population ranges and MIC50 and MIC90 values provide reference information for assessing new antibiotic agents and also provide a baseline for use in monitoring any future emergence of resistance.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25583720      PMCID: PMC4356840          DOI: 10.1128/AAC.04548-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Susceptibility of Yersinia pestis to novel and conventional antimicrobial agents.

Authors:  John Frean; Keith P Klugman; Lorraine Arntzen; Stanley Bukofzer
Journal:  J Antimicrob Chemother       Date:  2003-07-15       Impact factor: 5.790

Review 2.  Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

Authors:  T V Inglesby; D T Dennis; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; A M Friedlander; J Hauer; J F Koerner; M Layton; J McDade; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; M Schoch-Spana; K Tonat
Journal:  JAMA       Date:  2000-05-03       Impact factor: 56.272

3.  In vitro antimicrobial susceptibilities of strains of Yersinia pestis.

Authors:  M D Smith; D X Vinh; T T Nguyen; J Wain; D Thung; N J White
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

4.  Plasmids in Yersinia pestis.

Authors:  D M Ferber; R R Brubaker
Journal:  Infect Immun       Date:  1981-02       Impact factor: 3.441

5.  Antibiotic treatment of experimental pneumonic plague in mice.

Authors:  W R Byrne; S L Welkos; M L Pitt; K J Davis; R P Brueckner; J W Ezzell; G O Nelson; J R Vaccaro; L C Battersby; A M Friedlander
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  Lack of antimicrobial resistance in Yersinia pestis isolates from 17 countries in the Americas, Africa, and Asia.

Authors:  Sandra K Urich; Linda Chalcraft; Martin E Schriefer; Brook M Yockey; Jeannine M Petersen
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

7.  In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus.

Authors:  J A Frean; L Arntzen; T Capper; A Bryskier; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

8.  Genome plasticity in Yersinia pestis.

Authors:  Lyndsay Radnedge; Peter G Agron; Patricia L Worsham; Gary L Andersen
Journal:  Microbiology       Date:  2002-06       Impact factor: 2.777

9.  Virulence-associated plasmids from Yersinia enterocolitica and Yersinia pestis.

Authors:  D A Portnoy; S Falkow
Journal:  J Bacteriol       Date:  1981-12       Impact factor: 3.490

10.  Antibiotic susceptibilities of 94 isolates of Yersinia pestis to 24 antimicrobial agents.

Authors:  Eric Hernandez; Monique Girardet; Francoise Ramisse; Dominique Vidal; Jean-Didier Cavallo
Journal:  J Antimicrob Chemother       Date:  2003-11-12       Impact factor: 5.790

View more
  10 in total

1.  In Vitro and In Vivo Characterization of Tebipenem (TBP), an Orally Active Carbapenem, against Biothreat Pathogens.

Authors:  Nicholas P Clayton; Akash Jain; Stephanie A Halasohoris; Lisa M Pysz; Sanae Lembirik; Steven D Zumbrun; Christopher D Kane; Michael J Hackett; Denise Pfefferle; M Autumn Smiley; Michael S Anderson; Henry Heine; Gabriel T Meister; Michael J Pucci
Journal:  Antimicrob Agents Chemother       Date:  2021-02-16       Impact factor: 5.191

2.  In Vitro Antibiotic Susceptibilities of Francisella tularensis Determined by Broth Microdilution following CLSI Methods.

Authors:  Henry S Heine; Lynda Miller; Stephanie Halasohoris; Bret K Purcell
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis.

Authors:  Judith Steenbergen; S Ken Tanaka; Lynda L Miller; Stephanie A Halasohoris; Jeremy R Hershfield
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

4.  Mixed pneumonic plague and nosocomial MDR-bacterial infection of lung: a rare case report.

Authors:  Voahangy Andrianaivoarimanana; Eric Bertherat; Rojo Rajaonarison; Tiana Rakotondramaro; Christophe Rogier; Minoarisoa Rajerison
Journal:  BMC Pulm Med       Date:  2018-05-29       Impact factor: 3.317

5.  Genome Mining, Heterologous Expression, Antibacterial and Antioxidant Activities of Lipoamides and Amicoumacins from Compost-Associated Bacillus subtilis fmb60.

Authors:  Jie Yang; Qingzheng Zhu; Feng Xu; Ming Yang; Hechao Du; Xiaoying Bian; Zhaoxin Lu; Yingjian Lu; Fengxia Lu
Journal:  Molecules       Date:  2021-03-26       Impact factor: 4.411

6.  A novel mechanism of streptomycin resistance in Yersinia pestis: Mutation in the rpsL gene.

Authors:  Ruixia Dai; Jian He; Xi Zha; Yiting Wang; Xuefei Zhang; He Gao; Xiaoyan Yang; Juan Li; Youquan Xin; Yumeng Wang; Sheng Li; Juan Jin; Qi Zhang; Jixiang Bai; Yao Peng; Hailian Wu; Qingwen Zhang; Baiqing Wei; Jianguo Xu; Wei Li
Journal:  PLoS Negl Trop Dis       Date:  2021-04-22

7.  Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague.

Authors:  Yaron Vagima; David Gur; Moshe Aftalion; Sarit Moses; Yinon Levy; Arik Makovitzki; Tzvi Holtzman; Ziv Oren; Yaniv Segula; Ella Fatelevich; Avital Tidhar; Ayelet Zauberman; Shahar Rotem; Emanuelle Mamroud; Ida Steinberger-Levy
Journal:  Viruses       Date:  2022-03-26       Impact factor: 5.818

Review 8.  Antibiotic Therapy of Plague: A Review.

Authors:  Florent Sebbane; Nadine Lemaître
Journal:  Biomolecules       Date:  2021-05-12

9.  Rapid Antibiotic Susceptibility Testing of Tier-1 Agents Bacillus anthracis, Yersinia pestis, and Francisella tularensis Directly From Whole Blood Samples.

Authors:  Shahar Rotem; Ohad Shifman; Moshe Aftalion; David Gur; Tamar Aminov; Ronit Aloni-Grinstein
Journal:  Front Microbiol       Date:  2021-07-09       Impact factor: 5.640

10.  Transmission of Antimicrobial Resistant Yersinia pestis During a Pneumonic Plague Outbreak.

Authors:  Voahangy Andrianaivoarimanana; David M Wagner; Dawn N Birdsell; Birgit Nikolay; Faniry Rakotoarimanana; Lovasoa N Randriantseheno; Amy J Vogler; Jason W Sahl; Carina M Hall; Nawarat Somprasong; Simon Cauchemez; Herbert P Schweizer; Harimahefa Razafimandimby; Christophe Rogier; Minoarisoa Rajerison
Journal:  Clin Infect Dis       Date:  2022-03-01       Impact factor: 9.079

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.